PCSK9 inhibition: the data today and tomorrow.

Back

ESC Premium Access

PCSK9 inhibition: the data today and tomorrow.

Session: PSCK9 inhibition: a new horizon in LDL-C management

Topic: Lipids

Speaker: Professor S. Nicholls (Melbourne, AU)

About the speaker

Professor Stephen Nicholls

Monash University, Melbourne (Australia)

51 presentations

4 followers

6 more presentations in this session

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Speaker: Professor C. Cannon (Boston, US)

Access

LDL-C exposure and atherosclerosis progression.

Speaker: Professor A. Catapano (Milan, IT)

Access

Learnings and clinical insights from SPIRE.

Speaker: Doctor P. Ridker (Boston, US)

Access

Guidelines: commonalities and discrepancies.

Speaker: Doctor J. Robinson (Iowa, US)

Access

Identifying appropriate patients to treat: a case-based approach.

Speaker: Professor C. Cannon (Boston, US) Professor A. Catapano (Milan, IT) Professor S. Nicholls (Melbourne, AU) Doctor P. Ridker (Boston, US) Doctor J. Robinson (Iowa, US)

Access

Access the full session

PSCK9 inhibition: a new horizon in LDL-C management

Speakers: Professor S. Nicholls, Professor C. Cannon, Professor A. Catapano, Doctor P. Ridker, Doctor J. Robinson...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

PCSK9 inhibition: the data today and tomorrow.

About the speaker

Professor Stephen Nicholls

6 more presentations in this session

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

LDL-C exposure and atherosclerosis progression.

Learnings and clinical insights from SPIRE.

Guidelines: commonalities and discrepancies.

Identifying appropriate patients to treat: a case-based approach.

Access the full session

PSCK9 inhibition: a new horizon in LDL-C management

About the event

ESC Congress 2017

ESC 365 is supported by